drugset
drugset / Trial / NCT03462589

Single Ascending Oral Doses of SY-008 in Healthy Subjects

NCT03462589 ↗

Phase 1 Completed 54 enrolled Suzhou Yabao Pharmaceutical R&D Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase Ⅰ，single-center, randomized, double-blinded, placebo-controlled, single ascending dose trial of SY-008 in healthy subjects.

Timeline

Start
2018-08-02
Primary completion
2018-12-30
Completion
2018-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SY-008 Unknown 2 mg Oral
Subject SY-008 Unknown 6 mg Oral
Subject SY-008 Unknown 12 mg Oral
Subject SY-008 Unknown 18 mg Oral
Subject SY-008 Unknown 24 mg Oral
Subject SY-008 Unknown 30 mg Oral

Indications

diabetes mellitus